We came across a bullish thesis on Mereo Biopharma Group PLC (MREO) on substita by Jake Lamotta. In this article we will summarize the statement of the Bulls about Mreo. The share of Mereo Biopharma Group PLC (MREO) was traded on 16 April at $ 2one.
A biopharmaceutical facility with technicians who work on a production line of treatments and preventions.
Mereo Biopharma (MREO) seems to be one of the most incorrectly priced biotech opportunities after the wider XBI sale, and acts at $ 1.80 despite earlier enthusiasm around $ 4. Although unmistakably speculative and high risk, the core fundamentals remain largely unchanged. The recent weakness stems from the first interim lecture of the shortage of the Setrusumab-one result that was generally expected and never expected that he would impress, even by Mereo, his partner Ultragenyx, or sales analysts. However, attention now focuses on the upcoming second interim reading that will appear within a few months, which bears more favorable expectations. A positive result there can quickly increase the shares of the current levels, while a Miss would probably go further down, although optimism around the final readout remains intact. In the meantime, the prospects for a deal on Alvelestat remain uncertain, given the tough macro environment, but comments from Mereo’s CEO in the March Leerink Fireside chat suggested a stronger conviction than ever before. Despite the binary character of its upcoming catalysts, Mereo offers a unique asymmetrical risk/reward setup. The current appreciation reflects little of the upward potential of the company, making it a compelling opportunity for investors who are willing to virgins in exchange for a possible major efficiency.
Mereo Biopharma Group PLC (MREO) is not on our list of the 30 most popular shares among hedge funds. According to our database, 30 hedge fund portfolios Mreo held at the end of the fourth quarter, which was 25 in the previous quarter. Although we recognize the risk and potential of Mreo as an investment, our conviction is convinced that some AI shares have a greater promise to deliver a higher return, and to do this within a shorter time frame. If you are looking for an AI share that is promising than Mreo, but that acts with less than 5 times his income, view our report on the Cheapest AI stock.
Read next: 8 best wide canal shares to buy now And 30 most important AI shares according to BlackRock.
Publication: none. This article was originally published at Insider Monkey.
